Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023

Executive Summary

After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.

You may also be interested in...



Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies

Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.

Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset

The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.

Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer

The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel